Piston valve for serially connectable drug modules of a combination drug delivery device - Patents.com

The movable piston seal with a bypass chamber in the drug delivery device addresses needle stick risks and drug wastage, simplifying drug compounding and enabling safe, efficient preparation of synergistic drug combinations.

JP7577885B2Active Publication Date: 2024-11-05BRISTOL MYERS SQUIBB CO
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024083385
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-11-08
Filing Date
2024-05-22
Publication Date
2024-11-05
Estimated Expiration
2040-11-09

AI Technical Summary

Technical Problem

Existing drug compounding systems for intravenous infusion face challenges such as high risk of needle stick injuries, medication errors, drug wastage, and complexity, especially when preparing synergistic drug combinations, which are costly and difficult to automate.

Method used

A movable piston seal with a bypass chamber in a combination drug delivery device that seals the fluidic system during vial penetration and opens upon vacuum application, allowing fluid path establishment, reducing the need for large machines and minimizing waste.

Benefits of technology

The solution reduces the risk of needle stick injuries, minimizes drug wastage, and simplifies the preparation of drug combinations, enabling safe and efficient compounding even by non-specialists, including remote administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577885000001
    Figure 0007577885000001
  • Figure 0007577885000002
    Figure 0007577885000002
  • Figure 0007577885000003
    Figure 0007577885000003
Patent Text Reader

Abstract

To provide a valve structure for adjusting a fluid device of a module usable in a combination drug delivery device.SOLUTION: A valve includes: a piston valve 5 slidable that is capable of adjusting a discharge passage 3 from a medicine vial to selectively seal the passage; and a seal port 4 that is parallel to the vent hole 10 for selectively sealing an inflow path 2 to a medicine vial. Preferably, the current invention can adjust the valve by negative pressure given and can flow between modules serially connected forming the drug delivery device.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The field of the invention is the compounding and preparation of liquid drugs, particularly for intravenous infusion and direct injection into a patient. More specifically, the invention relates to sealing mechanisms for devices used in the preparation and compounding of combinations of two or more drugs. [Background technology]

[0002] It is common practice for the administration of drugs by intravenous infusion of drugs compounded in a pharmacy environment. Such drugs are usually supplied sterile in glass vials and may be supplied in the form of a solid or aqueous solution. If supplied in solid form, the drug needs to be prepared in a sterile aqueous diluent before being transferred to an infusion bag. Those skilled in the art will appreciate that such drug formulations typically include several excipients, e.g., buffers, pH adjusters, tonicity adjusters, stabilizers, etc. Typically, liquid drugs for intravenous infusion are compounded in an infusion bag in a pharmacy environment before being transferred for infusion to a patient. During compounding, compounding procedures are usually performed in a sterile compounding room (hood), since sterility of the drug needs to be maintained. Typically, a pharmacist or pharmacy technician (practitioner) prepares the drug according to an individual patient's prescription.

[0003] After ensuring that the hood is clear of all objects, the practitioner retrieves from the pharmacy inventory the vials of the medication required as per the prescription and verifies their identity and content. The verification process is assisted by a barcode scanner or other identification technology. The practitioner also retrieves from inventory all other necessary equipment required to safely prepare the medication for infusion, including the infusion bag itself, syringes, needles, transfer set, gloves, sharps disposal container, etc. Once all necessary equipment is gathered, the practitioner follows the procedure for preparation of the medication, which includes preparation of the solid medication by addition of diluents, sequentially removing the liquid medication from individual vials through transfer ports into an intravenous (IV) bag. Typically, this procedure is performed manually and uses multiple needles. The risk of needlestick injury to the practitioner increases with each needle required to perform the compounding of the medication. In the case of highly potent or toxic medications, such as cytotoxic drugs for chemotherapy, there is a significant risk of exposure for the practitioner.

[0004] To eliminate some of the risks associated with manual preparation, including exposure to hazardous drugs, and the risk of medication errors, drug compounding machines are known to those skilled in the art that automate many of the steps involved in drug preparation and compounding. Typically, such machines are complex electromechanical systems that implement sophisticated precision compounding mechanisms to accurately prepare liquid drugs. Aside from their cost, size, and complexity, many of the designs of such machines described in the art retrieve liquid drugs from stock storage and use only a portion of the drug in the container. Due to the need to maintain sterility, the unused drug liquid typically must be discarded, resulting in waste. This waste is a highly undesirable cost, as the cost of some drugs, especially biological drugs, is very high. When the wasted drugs are cytotoxic agents, their disposal creates significant environmental and safety hazards.

[0005] Recent advances in medicine, particularly in the treatment of cancer, have demonstrated that therapeutically beneficial effects can be achieved through the synergistic combination of two or more agents.

[0006] For example, recent clinical studies have shown that the combination of anti-PD-1 and CTLA4 checkpoint inhibitors can produce beneficial synergistic effects in some tumor types, leading to better clinical outcomes than can be achieved with the individual administration of each agent. Typically, such checkpoint inhibitors are monoclonal antibodies or immunoglobulin-type fragments derived from biotechnology. In some circumstances, it may be beneficial to combine such biologic agents with conventional chemotherapeutic agents, such as cytotoxic drugs.

[0007] Through the utilization of serially connectable drug modules as described in Applicant's co-pending applications (U.S. Provisional Patent Application No. 62 / 670,266, filed May 11, 2018; PCT Application No. PCT / US2019 / 031727, filed May 10, 2019; PCT Application No. PCT / 2019 / 031762, filed May 10, 2019; and PCT Application No. PCT / US2019 / 031791, filed May 10, 2019), drug combinations can be safely stored, shipped, and administered to patients, providing full flexibility while minimizing product waste. These drug modules utilize a common pre-fabricated vial primary container, which is punctured during administration with a spike located within the module, allowing the liquid drug within the vial to enter the internal fluid of the module. It is important that a sealing mechanism be present within the modular fluidic system to not only contain the liquid drug product within the modular fluidic system during the puncture process, but also to open the fluid pathway during use of the product to allow drug product flow. Because this product is intended to be disposable, the ideal sealing mechanism needs to be highly reliable and reproducible while keeping manufacturing costs low.

[0008] Applicant hereby expressly disclaims all warranties, including, but not limited to, the disclosures of U.S. Provisional Patent Application No. 62 / 670,266, filed May 11, 2018, PCT Application No. PCT / US2019 / 031727, filed May 10, 2019, PCT Application No. PCT / 2019 / 031762, filed May 10, 2019, and PCT Application No. PCT / US2019 / 031791, filed May 10, 2019, all of which are hereby incorporated by reference in their entirety. The combinatorial principles incorporated herein can address several challenges encountered in the preparation and compounding of drugs for intravenous infusion and can provide several advantages, including, but not limited to, streamlining pharmacy procedures, reducing the risk of medication errors, containing and protecting practitioners from highly potent or toxic drugs, reducing the risk of needlestick injuries, reducing or eliminating drug waste, and avoiding the need for complex and expensive drug compounding machines. As a result of these advantages in embodiments, the present invention may further enable the preparation and compounding of drugs for intravenous (IV) infusion at locations away from the pharmacy and by non-professionals, for example, by appropriately trained technicians or nurses in the patient's home. This feasibility is enhanced by the inherent transportability of the systems described herein. Summary of the Invention

[0009] According to the present invention, in a module usable in a combination drug delivery device, a movable piston seal with a bypass chamber put inline of the module's outlet fluidics provides a means to seal the module's fluidics from the atmosphere during vial penetration, while allowing a fluid path to open when a vacuum is applied to the outer surface of the piston seal.

[0010] Two lumen paths, inlet and outlet, in the spike that enter the drug chamber of the vial divide the fluid paths of the module. The inlet path allows liquid drug from the previous connected module to enter the pierced vial, and the outlet path transfers fluid from the vial to the subsequent module. A spring-loaded seal at the inlet path entrance is used to interface with the previous module. This seal ensures that the path is only opened upon connection with the module. Thus, when the vial is pierced, the inlet path is closed to the atmosphere and the vial contents cannot leak out.

[0011] During vial puncture, the amount of spike entering the vial displaces some of the liquid in the vial, slightly pressurizing the vial's contents and forcing them into the lumen of the spike. On the inlet side, this pressure is contained by a spring-loaded seal, while on the outlet side, the fluid enters the spike lumen and is sealed by a piston seal. When pressure is applied during the puncture process, the piston seal is pushed slightly, causing the liquid chamber to increase in volume, thus reducing the pressure caused by the puncture. On the other side of the piston seal is the outlet to the inlet of the following module. A small bypass is cut into the module body next to the piston seal, connecting the outlet chamber to the outlet fitting. When a vacuum source is applied to the outlet fitting, the piston moves, exposing the bypass port to the vial's fluid path and opening a path for fluid to move from the vial to the outlet fitting. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 shows a piston valve according to the present invention in a closed position. [Diagram 2] FIG. 2 shows a piston valve for releasing positive vial pressure according to the present invention. [Diagram 3] FIG. 3 shows a piston valve in an open position according to the present invention. [Figure 4] FIG. 4 shows a drug vial coupled to a valve in accordance with the present invention. [Diagram 5]FIG. 5 shows piston valves connected in series according to the present invention. [Figure 6] FIG. 6 shows the fluid paths of piston valves connected in series according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The present invention is particularly suited for use with serially connected drug modules, especially in forming a fluid pathway therebetween. While the present invention is shown in the context of a single module 9, it will be understood that the present invention will work with multiple similarly formed modules 9 connected in series. As shown in Figures 1 and 4, each of the modules 9 includes a valve having a vial spike 1 that is used to pierce a vial septum S that extends into the interior volume V of a liquid-filled drug vial DV. The free distal end 11 of the vial spike 1 may be sharpened to facilitate piercing the vial septum S. The vial spike 1 must be of sufficient length to fully pierce the septum S to access the interior volume V.

[0014] The vial spike 1 includes two lumens, the inlet path 2 and the outlet path 3, which divide the fluidic system of the module into separate circuits. With the vial spike 1 penetrating the septum S, both the inlet path 2 and the outlet path 3 are open at the free end 11 of the vial spike 1 and connect with the internal volume V of the drug vial DV. The inlet path 2 extends from the internal volume V of the drug vial DV to an inlet opening 12 that is selectively sealed by a spring-loaded seal port 4. An air vent 10 is present on the inlet path 2, preferably between the free end 11 and the inlet opening 12, to allow air to flow into the drug vial DV to replace the fluid during transfer, if necessary. Preferably, the air vent 10 is a one-way vent that allows gas to flow into the inlet path 2, which is normally closed. The outlet path 3 extends from the internal volume V of the drug vial DV to an outlet chamber 6. The piston valve 5 is slidably seated inside the exhaust chamber 6 and forms a seal against the chamber inner wall 13. The piston valve 5 may include a radial seal 14 that makes sealing contact with the wall 13 to form a seal while allowing the piston valve 5 to slide within the exhaust chamber 6.

[0015] The piston valve 5 forms a seal within the discharge chamber 6 to define a first chamber portion 6a and a second chamber portion 6b which are adjustable in size in response to movement of the piston valve 5 within the discharge chamber 6 while maintaining a seal therebetween. A discharge passage 3 connects with the first chamber portion 6a. A discharge fitting 7 is provided which connects with the discharge chamber 6, and in particular with the second discharge chamber 6b.

[0016] 1, the piston valve 5 is disposed in a first position at the inner end of the discharge chamber 6 to prevent fluid entering from the discharge lumen 3 from accessing the discharge fitting 7. A bypass passage 8 connects the discharge chamber 6 to the discharge fitting 7. Specifically, the bypass passage 8 terminates at an opening 15 in a wall 13 of the discharge chamber 6. With the piston valve 5 in the first position, the first chamber portion 6a is sealed from the bypass passage 8.

[0017] In this arrangement (piston valve 5 in first position), as shown in Figure 2, pressurized fluid expelled from drug vial DV as a result of vial spike 1 puncturing septum S is contained in inlet path 2 by spring-loaded sealed port 4, while fluid entering outlet path 3 is contained within first chamber portion 6a behind piston valve 5. As shown in Figure 2, pressure within the fluid may cause piston valve 5 to move slightly. This movement in position causes the pressure within drug vial DV and the fluid path to equilibrate to a negligible amount.

[0018] As shown in FIG. 3, during fluid transfer, a source of negative pressure, e.g., vacuum, is provided to the discharge fitting 7, thereby discharging air from the bypass passage 8 and the discharge chamber 6, specifically the second chamber portion 6b. This creates a pressure differential across the piston valve 5, causing the piston valve 5 to slide along the discharge chamber 6 toward the discharge fitting 7. This increases the volume of the first chamber portion 6a. Eventually, as the piston valve 5 continues to move, it passes through the bypass passage 8, thereby allowing the first chamber portion 6a to connect with the bypass passage 8 along with the discharge path 3. As shown in FIG. 3, when the bypass passage 8 conveys the vacuum, fluid can be discharged from the vial through the discharge path 3, bypassing the piston valve 5 through the bypass passage 8, and through the discharge fitting 7.

[0019] As shown in Figures 5 and 6, multiple modules 9 may be coupled in series with the discharge fitting 7a of the secondary module 9a breaking through the sealing port 4 of the adjacent module 9, so that the discharge fitting 7a connects with the inlet opening 12 of the adjacent module 9. The secondary module 9a is formed similarly to the module 9, with similar parts similarly numbered, but further indicated with the letter "a" (except for the discharge chamber of the secondary module, shown as 6'). The coupled arrangement may define a fluid path from the drug vial DV coupled to the vial spike 1a of the secondary module 9a to the discharge fitting 7 of the module 9, via the drug vial DV coupled to the vial spike 1, as shown diagrammatically in Figure 6. This fluid path is achieved by the sliding movement of the piston valve 5a caused by the application of negative pressure to the discharge fitting 7a via the discharge path 3 and the inlet path 2 of the module 9. As above, flow bypasses the piston valve 5a in the bypass passage 8a upon sufficient sliding displacement of the piston valve 5a. This arrangement allows for serial coupling of modules 9, with each drug vial DV aligned to define a single flow path acted upon by a single negative pressure source.

[0020] It should also be noted that the vent 10 may be positioned to terminate in a vent opening 16 positioned to be exposed to the open atmosphere. Preferably, the vent opening 16 is located on a common wall with the sealing port 4, such that the adjacent joined module 9a covers the vent opening 16. This obstruction restricts the venting of the module 9, thereby maximizing the negative pressure applied to the adjacent joined module 9a. The obstructed venting can continue through the modules joined in series, with the last module 9 (e.g., module 9a) having an exposed vent opening 16, thereby providing venting for the entire series.

Claims

1. A module (9) for use in a combination drug delivery device, said module being configured to receive a drug vial (DV) provided with a septum, said module comprising: a vial spike (1) formed to penetrate the septum (S) of the drug vial (DV), the vial spike (1) being configured such that a free end of the vial spike (1) is positioned inside the septum (S), the vial spike (1) including an inlet path (2) opening at the free end (11) and extending along the vial spike (1) to an inlet opening (12), and an outlet path (3) opening at the free end and extending along the vial spike (1) to an outlet chamber (6), the outlet path (3) being separate from the inlet path (2); a sealing port (4) for selectively sealing said inlet opening (12); a vent (10) connected to the inlet path (2) between the inlet opening (12) and the free end (11); a slidable piston valve (5) disposed within the discharge chamber (6), the piston valve (5) forming a seal within the discharge chamber (6) to define a first chamber portion (6a) and a second chamber portion (6b), the discharge path (3) connecting with the first chamber portion (6a); a discharge joint (7) connected to the second chamber portion (6b); a bypass passage (8) extending between the discharge fitting (7) and an opening in the discharge chamber (6); In an initial state, the piston valve is positioned at a first position where the first chamber portion is sealed from the bypass passage, When a negative pressure is applied through the exhaust joint, the piston valve moves to a second position in which the first chamber portion is connected to the bypass passage; The vent (10) terminates in a vent opening (16) remote from the inlet path (2), and the sealing port (4) and the vent opening (16) are located in a common wall of the module (9). Module.

2. 2. The module of claim 1, wherein the vent (10) is a one-way vent that is normally closed and allows gas to flow into the inlet path (2).

3. 2. The module of claim 1, wherein the piston valve (5) includes a radial seal in sealing contact with a wall of the exhaust chamber (6).

4. A first module (9), comprising: a first vial spike (1) having a first free end, the first vial spike (1) including a first inlet path (2) opening at the first free end and extending along the first vial spike (1) to a first inlet opening (12), and a first outlet path (3) opening at the first free end and extending along the first vial spike (1) to a first outlet chamber (6), the first outlet path (3) being separate from the first inlet path (2); a first sealing port (4) selectively sealing the first inlet opening (12); a first vent (10) connected to the first inlet path (2) between the first inlet opening (12) and the first free end, the first vent (10) terminating in a first vent opening (16) remote from the first inlet path (2), the first sealing port (4) and the first vent opening (16) being located in a common wall of the first module (9); a first slidable piston valve (5) disposed within the first discharge chamber (6), the first piston valve (5) forming a seal within the first discharge chamber (6) to define a first primary chamber portion (6a) and a second primary chamber portion (6b), the first discharge path connecting with the first primary chamber portion (6a); a first discharge fitting (7) connected to said second primary chamber portion (6b); a first bypass passage (8) extending between the first discharge fitting (7) and a first opening in the first discharge chamber (6); A first module (9) including: A second module (9a), said second module (9a) comprising: a second vial spike (1a) having a second free end, the second vial spike (1a) including a second inlet path (2a) opening at the second free end and extending along the second vial spike (1a) to a second inlet opening (12a), and a second outlet path (3a) opening at the second free end and extending along the second vial spike (1a) to a second outlet chamber (6'), the second outlet path (3a) being separate from the second inlet path (2a); a second sealing port (4a) selectively sealing the second inlet opening (12a); a second vent (10a) connected to the second inlet path (2a) between the second inlet opening (12a) and the second free end; a second slidable piston valve (5a) disposed within said second discharge chamber (6'), said second piston valve (5a) forming a seal within said second discharge chamber (6') to define a first secondary chamber portion (6'a) and a second secondary chamber portion (6'b), said second discharge path (3a) connecting with said first secondary chamber portion (6'a); a second discharge fitting (7a) connected to the second secondary chamber portion (6'b); a second bypass passage (8a) extending between the second discharge fitting (7a) and a second opening in the second discharge chamber (6'); and a second module (9a) comprising: the second module (9a) is coupled to the first module (9) such that the second discharge fitting (7a) extends through the first sealing port (4) and connects with the first inlet opening (12); In an initial state, the first piston valve (5) is located in a first position in which the first primary chamber portion (6a) is sealed from the first bypass passage (8); When a negative pressure is applied via the first exhaust fitting (7), the first piston valve (5) moves to a second position in which the first primary chamber portion (6a) connects with the first bypass passage (8); When the first piston valve (5) is in the second position, a negative pressure is applied to the second discharge joint (7a) via the first discharge path (3) and the first inlet path (2); When the second module (9a) is coupled to the first module (9), the second module (9a) closes the first ventilation opening (16) to restrict ventilation through the first ventilation opening (16). combination.

5. 5. The combination according to claim 4, wherein when the second module (9a) is coupled to the first module (9), the second vent (10a) is exposed while the second sealing port (4a) seals the second inlet opening (12a).

6. 5. The combination according to claim 4, wherein when a negative pressure is applied via the second discharge fitting (7a), the second piston valve (5a) moves within the second discharge chamber (6') such that the first secondary chamber part (6'a) is connected with the second bypass passage (8a).

Citation Information

Patent Citations

  • Storage device for single or multiple containers

    JP2018519141A